Theravance Biopharma-The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself

The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself

公司动态 - Theravance Biopharma公司表示其可能将被出售这一表态源于其针对一种罕见病的三期临床试验失败[1] - 该生物科技公司的股价因此大幅下挫[1] 研发进展 - 公司针对一种罕见病的三期临床试验宣告失败[1]

Theravance Biopharma-The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself - Reportify